Biogen Idec (BIIB: Quote) said detailed positive data from CONFIRM, the second Phase 3 trial of oral BG-12, or dimethyl fumarate, in people with relapsing-remitting multiple sclerosis, or RRMS, will be presented in three platform presentations at the 64th Annual Meeting of the American Academy of Neurology in New Orleans.
In CONFIRM, BG-12 demonstrated efficacy across a variety of clinical and radiological outcome measures, as well as favorable safety and tolerability profiles. These data, along with results from BG-12's first Phase 3 study, DEFINE, were included in regulatory applications that were submitted to U.S. and EU regulatory agencies early this year.
Earlier this year, Biogen Idec announced that it had submitted a New Drug Application to the U.S. Food and Drug Administration for marketing approval of BG-12 in the United States and a Marketing Authorisation Application to the European Medicines Agency, or EMA, for review in the European Union. The EMA has validated Biogen Idec's Marketing Authorisation Application and is reviewing the BG-12 data package. Biogen Idec is awaiting formal acceptance of its NDA for review by the FDA.
Click here to receive FREE breaking news email alerts for Biogen Idec and others in your portfolio
by RTT Staff Writer
For comments and feedback: email@example.com